News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

The Expanding Role of CAR T Cells in Lymphoma and Leukemia

EP. 1: Rationale for Further Development of CAR T-Cell therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 2: CAR T-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 3: R/R Large B-Cell Therapy in Managing Various Lymphomas

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 4: The Importance of Antigen Loss in R/R Disease

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 5: Liso-cel Therapy in R/R Large B-Cell Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 6: LDH and ECOG Performance Tests

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 7: ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 8: CAR T-Cell Therapy for Follicular Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 9: R/R NHL: Candidate Identification and Referrals

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 10: LBCL Therapy: The Right Therapy

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 11: CAR T Cells and Lymphoma Adverse Events

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 12: CAR T-Cell Therapy’s Future for Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 13: Allogenic CAR T-Cell Therapy in Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 14: Developing CAR T-Cell Trials

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

EP. 15: Ongoing Issues in CAR T-Cell Therapy and Lymphoma

ByStephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Matthew J. Frigault, MD, Massachusetts General Hospital Cancer Center,David Miklos, MD, Stanford University,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

July 2nd 2020

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL